

# Pedro Romero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7031521/publications.pdf>

Version: 2024-02-01

313  
papers

27,298  
citations

5558

82  
h-index

7718

150  
g-index

322  
all docs

322  
docs citations

322  
times ranked

30154  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lighting up the tumor fire with low-dose irradiation. <i>Trends in Immunology</i> , 2022, 43, 173-179.	2.9	26
2	The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function. <i>Cell Metabolism</i> , 2022, 34, 731-746.e9.	7.2	63
3	The Era of Cytotoxic CD4 T Cells. <i>Frontiers in Immunology</i> , 2022, 13, 867189.	2.2	49
4	Enforced PGC-1 $\beta$ expression promotes CD8 T cell fitness, memory formation and antitumor immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1761-1771.	4.8	73
5	Gain of HIF1 Activity and Loss of miRNA <i>let-7d</i> Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis. <i>Cancer Research</i> , 2021, 81, 594-605.	0.4	18
6	Human primed ILCs support endothelial activation through NF- $\kappa$ B signaling. <i>ELife</i> , 2021, 10, .	2.8	7
7	Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. <i>Science Advances</i> , 2021, 7, .	4.7	157
8	Fibroblast Activation Protein $\beta$ -Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021, 27, 4036-4053.	3.2	31
9	CD40 Agonist Targeted to Fibroblast Activation Protein $\beta$ Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4054-4065.	3.2	18
10	Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. <i>Vaccines</i> , 2021, 9, 454.	2.1	11
11	Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. <i>Nature Immunology</i> , 2021, 22, 746-756.	7.0	160
12	PPAR $\delta$ drives IL-33-dependent ILC2 pro-tumoral functions. <i>Nature Communications</i> , 2021, 12, 2538.	5.8	44
13	CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 209-214.	1.4	4
14	Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	74
15	Recombinant fusion proteins for targeting dendritic cell subsets in therapeutic cancer vaccine. <i>Methods in Enzymology</i> , 2020, 632, 521-543.	0.4	7
16	Generation of affinity ranged antigen-expressing tumor cell lines. <i>Methods in Enzymology</i> , 2020, 632, 503-519.	0.4	0
17	miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 111-123.	2.0	15
18	Assessment of memory formation by metabolically engineered antigen-specific CD8 T cells. <i>Methods in Enzymology</i> , 2020, 631, 77-90.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Detecting and analyzing murine innate lymphoid cells. <i>Methods in Enzymology</i> , 2020, 631, 329-342.	0.4	2
20	Metabolic and epigenetic regulation of T-cell exhaustion. <i>Nature Metabolism</i> , 2020, 2, 1001-1012.	5.1	167
21	An Immunomodulatory Gallotannin-Rich Fraction From <i>Caesalpinia spinosa</i> Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 584959.	2.2	21
22	An optimized antigen-protein fusion. <i>Nature Biomedical Engineering</i> , 2020, 4, 583-584.	11.6	6
23	Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 340.	2.2	27
24	Moving cancer immunotherapy forward through the <i>Journal for ImmunoTherapy of Cancer (JITC)</i> , 2020, 8, e000001.		2
25	Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. <i>European Journal of Cancer</i> , 2020, 135, 173-182.	1.3	32
26	Immunosuppressive Mediators Impair Proinflammatory Innate Lymphoid Cell Function in Human Malignant Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 556-564.	1.6	21
27	Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells. <i>Journal of Leukocyte Biology</i> , 2020, 108, 723-737.	1.5	28
28	CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival. <i>Cancer Research</i> , 2019, 79, 5245-5259.	0.4	35
29	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
30	Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 2121.	2.2	35
31	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. <i>Nature Immunology</i> , 2019, 20, 206-217.	7.0	51
32	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1859-1868.	3.3	62
33	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. <i>Frontiers in Immunology</i> , 2019, 10, 925.	2.2	288
34	High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4320-4331.	3.2	15
35	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
36	MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 1013-1024.	1.6	24

#	ARTICLE	IF	CITATIONS
37	Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2019, 7, 707-718.	1.6	94
38	Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 425-441.	12.5	452
39	The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. <i>Cell Stem Cell</i> , 2019, 24, 405-418.e7.	5.2	143
40	Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. <i>Frontiers in Immunology</i> , 2019, 10, 294.	2.2	27
41	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. <i>Blood Advances</i> , 2019, 3, 3674-3687.	2.5	40
42	CD73 expression in normal and pathological human hepatobiliopancreatic tissues. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 467-478.	2.0	27
43	Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic $\beta$ Cell Death and May Contribute to Type 1 Diabetes Development. <i>Cell Metabolism</i> , 2019, 29, 348-361.e6.	7.2	200
44	Mitochondria-Endoplasmic Reticulum Contact Sites Function as Immunometabolic Hubs that Orchestrate the Rapid Recall Response of Memory CD8+ T Cells. <i>Immunity</i> , 2018, 48, 542-555.e6.	6.6	133
45	Sensitive and frequent identification of high avidity neo-epitope-specific CD8 + T cells in immunotherapy-naive ovarian cancer. <i>Nature Communications</i> , 2018, 9, 1092.	5.8	122
46	Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints. <i>Cancer Research</i> , 2018, 78, 3604-3618.	0.4	53
47	Rationale for immunological approaches to breast cancer therapy. <i>Breast</i> , 2018, 37, 187-195.	0.9	23
48	Metabolic Control of CD8+ T Cell Fate Decisions and Antitumor Immunity. <i>Trends in Molecular Medicine</i> , 2018, 24, 30-48.	3.5	158
49	Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 2076.	2.2	76
50	Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPAR $\gamma$ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth. <i>Cancer Research</i> , 2018, 78, 6447-6461.	0.4	18
51	Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth. <i>Frontiers in Oncology</i> , 2018, 8, 356.	1.3	24
52	CART cells are prone to Fas- and DR5-mediated cell death. , 2018, 6, 71.		53
53	PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells. <i>Journal of Immunology</i> , 2018, 201, 792-803.	0.4	31
54	CD73 expression and clinical significance in human metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 26659-26669.	0.8	39

#	ARTICLE	IF	CITATIONS
55	Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8 <sup>+</sup> T cells. <i>Onc Immunology</i> , 2017, 6, e1318234.	2.1	12
56	Curtailed T <sub>H</sub> 1 cell activation curbs effector differentiation and generates CD8 <sup>+</sup> T cells with a naturally occurring memory stem cell phenotype. <i>European Journal of Immunology</i> , 2017, 47, 1468-1476.	1.6	21
57	The Vast Universe of T Cell Diversity: Subsets of Memory Cells and Their Differentiation. <i>Methods in Molecular Biology</i> , 2017, 1514, 1-17.	0.4	3
58	Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle Invasive Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 717-725.	3.2	24
59	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1918.	2.2	72
60	TCR-ligand dissociation rate is a robust and stable biomarker of CD8 <sup>+</sup> T cell potency. <i>JCI Insight</i> , 2017, 2, .	2.3	46
61	CD8 T Lymphocytes in Antitumor Immunity. , 2016, , 434-440.		0
62	Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients. <i>Frontiers in Immunology</i> , 2016, 7, 573.	2.2	73
63	Piezoresistive Membrane Surface Stress Sensors for Characterization of Breath Samples of Head and Neck Cancer Patients. <i>Sensors</i> , 2016, 16, 1149.	2.1	22
64	NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. <i>Nature Communications</i> , 2016, 7, 10554.	5.8	40
65	IL-21 Induced MHC Class II <sup>+</sup> NK Cells Promote the Expansion of Human Uncommitted CD4 <sup>+</sup> Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner. <i>Journal of Immunology</i> , 2016, 197, 85-96.	0.4	30
66	Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8 <sup>+</sup> and CD4 <sup>+</sup> T-cell responses with multiple specificities including a novel DR7-restricted epitope. <i>Onc Immunology</i> , 2016, 5, e1216290.	2.1	50
67	The Human Vaccines Project: A roadmap for cancer vaccine development. <i>Science Translational Medicine</i> , 2016, 8, 334ps9.	5.8	162
68	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
69	Epitope located <i>N</i> -glycans impair the MHC epitope generation and presentation. <i>Electrophoresis</i> , 2016, 37, 1448-1460.	1.3	14
70	Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model. <i>Cell Death and Disease</i> , 2016, 7, e2243-e2243.	2.7	47
71	Mammalian Target of Rapamycin Complex 2 Controls CD8 <sup>+</sup> T Cell Memory Differentiation in a Foxo1-Dependent Manner. <i>Cell Reports</i> , 2016, 14, 1206-1217.	2.9	111
72	Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells. <i>EBioMedicine</i> , 2016, 4, 50-61.	2.7	89

#	ARTICLE	IF	CITATIONS
73	An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. <i>Oncotarget</i> , 2016, 7, 21199-21221.	0.8	32
74	JITC launches a new section: commentary and editorials. , 2015, 3, 28.		0
75	Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer. , 2015, 3, 49.		0
76	Consensus nomenclature for CD8 <sup>+</sup> T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	2.1	119
77	CD127+ innate lymphoid cells are dysregulated in treatment naive acute myeloid leukemia patients at diagnosis. <i>Haematologica</i> , 2015, 100, e257-e260.	1.7	69
78	Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6140-6145.	3.3	498
79	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15.		57
80	Local <i>Salmonella</i> immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. <i>Oncolmmunology</i> , 2015, 4, e1016697.	2.1	11
81	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. <i>Oncolmmunology</i> , 2015, 4, e1029702.	2.1	17
82	The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. <i>Blood</i> , 2015, 126, 1019-1019.	0.6	0
83	Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. <i>Journal of Clinical Investigation</i> , 2014, 124, 1810-1820.	3.9	340
84	Deciphering the unusual HLA-A2/MelanA/MART-1-specific TCR repertoire in humans. <i>European Journal of Immunology</i> , 2014, 44, 2567-2570.	1.6	9
85	Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1199-1211.	2.0	30
86	iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. , 2014, 2, 39.		16
87	Mammalian Target of Rapamycin Complex 1 Orchestrates Invariant NKT Cell Differentiation and Effector Function. <i>Journal of Immunology</i> , 2014, 193, 1759-1765.	0.4	62
88	The role of the reporting framework MIATA within current efforts to advance immune monitoring. <i>Journal of Immunological Methods</i> , 2014, 409, 6-8.	0.6	4
89	Successful engineering cancer immunotherapy. <i>European Journal of Immunology</i> , 2014, 44, 318-320.	1.6	2
90	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. <i>Nature Reviews Immunology</i> , 2014, 14, 768-774.	10.6	248

#	ARTICLE	IF	CITATIONS
91	Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes. <i>Cancer Immunology Research</i> , 2014, 2, 436-447.	1.6	165
92	A microRNA profile of human CD8+ regulatory T cells and characterization of the effects of microRNAs on Treg cell-associated genes. <i>Journal of Translational Medicine</i> , 2014, 12, 218.	1.8	37
93	MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. <i>Journal of Translational Medicine</i> , 2014, 12, 97.	1.8	69
94	Intravaginal and Subcutaneous Immunization Induced Vaccine Specific CD8 T Cells and Tumor Regression in the Bladder. <i>Journal of Urology</i> , 2014, 191, 814-822.	0.2	14
95	CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 747-760.	2.0	34
96	Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity. <i>Cancer Research</i> , 2013, 73, 6597-6608.	0.4	86
97	Prognostic value of arginase expression and regulatory T cell infiltration in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2013, 132, E85-93.	2.3	94
98	JTMs Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section. <i>Journal of Translational Medicine</i> , 2013, 11, 2.	1.8	2
99	MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer. <i>Immunity</i> , 2013, 38, 742-753.	6.6	278
100	Vaccination Route Matters for Mucosal Tumors. <i>Science Translational Medicine</i> , 2013, 5, 172fs4.	5.8	16
101	Prediction of Cross-Recognition of Peptide-HLA A2 by Melan-A-Specific Cytotoxic T Lymphocytes Using Three-Dimensional Quantitative Structure-Activity Relationships. <i>PLoS ONE</i> , 2013, 8, e65590.	1.1	3
102	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	9
103	Peptide and Protein-Based Cancer Vaccines. , 2013, , 111-146.		2
104	SHP-1 phosphatase activity counteracts increased T cell receptor affinity. <i>Journal of Clinical Investigation</i> , 2013, 123, 1044-1056.	3.9	109
105	Persistence of EBV Antigen-Specific CD8 T Cell Clonotypes during Homeostatic Immune Reconstitution in Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e78686.	1.1	15
106	Structured reporting of T cell assay results. <i>Cancer Immunity</i> , 2013, 13, 13.	3.2	5
107	What is the influence of vaccination's routes on the regression of tumors located at mucosal sites?. <i>Oncolmmunology</i> , 2012, 1, 242-243.	2.1	6
108	Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells. <i>Cancer Research</i> , 2012, 72, 4629-4641.	0.4	168

#	ARTICLE	IF	CITATIONS
109	Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8 <sup>+</sup> T Cell Responsiveness. <i>Journal of Biological Chemistry</i> , 2012, 287, 23068-23078.	1.6	121
110	Human melanoma-specific CD8 <sup>+</sup> T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. <i>Oncoimmunology</i> , 2012, 1, 467-530.	2.1	14
111	Saponins from the Spanish saffron <i>Crocus sativus</i> are efficient adjuvants for protein-based vaccines. <i>Vaccine</i> , 2012, 30, 388-397.	1.7	19
112	MicroRNA Profile of Circulating CD4-positive Regulatory T Cells in Human Adults and Impact of Differentially Expressed MicroRNAs on Expression of Two Genes Essential to Their Function. <i>Journal of Biological Chemistry</i> , 2012, 287, 9910-9922.	1.6	80
113	NLR5 Deficiency Selectively Impairs MHC Class I- Dependent Lymphocyte Killing by Cytotoxic T Cells. <i>Journal of Immunology</i> , 2012, 188, 3820-3828.	0.4	116
114	Melanoma Vaccines. , 2012, , 207-232.		0
115	Virus-like particles induce robust human T-helper cell responses. <i>European Journal of Immunology</i> , 2012, 42, 330-340.	1.6	69
116	TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 1607-1614.	0.4	105
117	Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression. <i>Cancer Research</i> , 2011, 71, 5976-5986.	0.4	223
118	Harmonization of Immune Biomarker Assays for Clinical Studies. <i>Science Translational Medicine</i> , 2011, 3, 108ps44.	5.8	87
119	Pattern and clinical significance of cancer testis gene expression in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2011, 128, 2625-2634.	2.3	66
120	MAGE-A3 and MAGE-A4 specific CD4 <sup>+</sup> T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 23-35.	2.0	23
121	A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. <i>Journal of Translational Medicine</i> , 2011, 9, 108.	1.8	25
122	Differentiation associated regulation of microRNA expression in vivo in human CD8 <sup>+</sup> T cell subsets. <i>Journal of Translational Medicine</i> , 2011, 9, 44.	1.8	67
123	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. <i>European Journal of Immunology</i> , 2011, 41, 2217-2228.	1.6	69
124	Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. <i>International Journal of Cancer</i> , 2011, 129, 762-772.	2.3	29
125	Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation. <i>Immunity</i> , 2011, 34, 213-223.	6.6	810
126	Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 15318-15323.	3.3	28



#	ARTICLE	IF	CITATIONS
127	Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. <i>Journal of Clinical Investigation</i> , 2011, 121, 2350-2360.	3.9	707
128	Impact of 3 Different Short-term Chemotherapy Regimens on Lymphocyte-depletion and Reconstitution in Melanoma Patients. <i>Journal of Immunotherapy</i> , 2010, 33, 723-734.	1.2	21
129	Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. <i>Journal of Immunotherapy</i> , 2010, 33, 848-858.	1.2	131
130	Coexpression of the T-cell receptor constant $\hat{1}\pm$ domain triggers tumor reactivity of single-chain TCR-transduced human T cells. <i>Blood</i> , 2010, 115, 5154-5163.	0.6	48
131	Induction of human papillomavirus oncogene-specific CD8 T cell effector responses in the genital mucosa of vaccinated mice. <i>International Journal of Cancer</i> , 2010, 126, 2469-2478.	2.3	17
132	Valproate Treatment of Human Cord Blood CD4-positive Effector T Cells Confers on Them the Molecular Profile (MicroRNA Signature and FOXP3 Expression) of Natural Regulatory CD4-positive Cells through Inhibition of Histone Deacetylase. <i>Journal of Biological Chemistry</i> , 2010, 285, 20481-20491.	1.6	22
133	Dendritic Cell-Specific Antigen Delivery by Coronavirus Vaccine Vectors Induces Long-Lasting Protective Antiviral and Antitumor Immunity. <i>MBio</i> , 2010, 1, .	1.8	40
134	Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function. <i>Journal of Immunology</i> , 2010, 184, 4936-4946.	0.4	196
135	Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. <i>Seminars in Immunology</i> , 2010, 22, 144-154.	2.7	39
136	Quantitative Multiparameter Assays to Measure the Effect of Adjuvants on Human Antigen-Specific CD8 T-Cell Responses. <i>Methods in Molecular Biology</i> , 2010, 626, 231-249.	0.4	2
137	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. <i>Journal of Clinical Investigation</i> , 2010, 120, 157-167.	3.9	252
138	Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts. <i>Cancer Research</i> , 2009, 69, 8085-8093.	0.4	40
139	The Cooperative Induction of Hypoxia-Inducible Factor-1 $\hat{1}\pm$ and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis. <i>Journal of Immunology</i> , 2009, 182, 3510-3521.	0.4	175
140	Dominant Human CD8 T Cell Clonotypes Persist Simultaneously as Memory and Effector Cells in Memory Phase. <i>Journal of Immunology</i> , 2009, 182, 6718-6726.	0.4	18
141	Expression Hierarchy of T Cell Epitopes from Melanoma Differentiation Antigens: Unexpected High Level Presentation of Tyrosinase-HLA-A2 Complexes Revealed by Peptide-Specific, MHC-Restricted, TCR-Like Antibodies. <i>Journal of Immunology</i> , 2009, 182, 6328-6341.	0.4	47
142	Fine Structural Variations of $\hat{1}\pm$ TCRs Selected by Vaccination with Natural versus Altered Self-Antigen in Melanoma Patients. <i>Journal of Immunology</i> , 2009, 183, 5397-5406.	0.4	48
143	Enrichment of Human CD4+ $\hat{V}\hat{1}\pm 24/\hat{V}\hat{1}\pm 11$ Invariant NKT Cells in Intrahepatic Malignant Tumors. <i>Journal of Immunology</i> , 2009, 182, 5140-5151.	0.4	103
144	Clonotype Selection and Composition of Human CD8 T Cells Specific for Persistent Herpes Viruses Varies with Differentiation but Is Stable Over Time. <i>Journal of Immunology</i> , 2009, 183, 319-331.	0.4	69

#	ARTICLE	IF	CITATIONS
145	Allorestricted T lymphocytes with a high avidity T cell receptor towards NY-ESO-1 have potent anti-tumor activity. <i>International Journal of Cancer</i> , 2009, 125, 649-655.	2.3	25
146	Human natural Treg microRNA signature: Role of microRNA-31 and microRNA-21 in FOXP3 expression. <i>European Journal of Immunology</i> , 2009, 39, 1608-1618.	1.6	252
147	Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1701-1713.	2.0	60
148	"MIATA" Minimal Information about T Cell Assays. <i>Immunity</i> , 2009, 31, 527-528.	6.6	178
149	Cross-presenting human T cells induce robust CD8 <sup>+</sup> T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2307-2312.	3.3	229
150	Toll-like receptor 3 is necessary for dsRNA adjuvant effects. <i>Vaccine</i> , 2009, 27, 1841-1847.	1.7	18
151	Announcing the Tumor Immunology and Biological Cancer Therapy section (edited by iSBTc) of the <i>Journal of Translational Medicine</i> . <i>Journal of Translational Medicine</i> , 2009, 7, 80.	1.8	2
152	Recent advances and hurdles in melanoma immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 711-723.	1.5	43
153	Vaccination of Melanoma Patients With Melan-A/Mart-1 Peptide and Klebsiella Outer Membrane Protein P40 as an Adjuvant. <i>Journal of Immunotherapy</i> , 2009, 32, 875-883.	1.2	16
154	Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 303-315.	2.0	193
155	Selective accumulation of differentiated FOXP3 <sup>+</sup> CD4 <sup>+</sup> T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1795-1805.	2.0	65
156	Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. <i>Arthritis and Rheumatism</i> , 2008, 58, 2307-2317.	6.7	351
157	Lack of Functionally Active Melan-A26-35-Specific T Cells in the Blood of HLA-A2+ Vitiligo Patients. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1977-1980.	0.3	6
158	Current State of Vaccine Therapies in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, S28-S36.	1.1	23
159	Tumour immunity: effector response to tumour and role of the microenvironment. <i>Lancet, The</i> , 2008, 371, 771-783.	6.3	476
160	Molecular Design of the CD28 Interface Favors Specific Pairing of Introduced TCRs in Human T Cells. <i>Journal of Immunology</i> , 2008, 180, 391-401.	0.4	87
161	Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3849-3854.	3.3	136
162	Characterization of Melan-A reactive memory CD8 <sup>+</sup> T cells in a healthy donor. <i>International Immunology</i> , 2008, 20, 1087-1096.	1.8	14

#	ARTICLE	IF	CITATIONS
163	Distinct sets of $\hat{1}\hat{2}$ TCRs confer similar recognition of tumor antigen NY-ESO-1 <sub>157</sub> by interacting with its central Met/Trp residues. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15010-15015.	3.3	39
164	Intralesional Adenovirus-mediated Interleukin-2 Gene Transfer for Advanced Solid Cancers and Melanoma. Molecular Therapy, 2008, 16, 985-994.	3.7	41
165	An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. Cancer Immunity, 2008, 8, 6.	3.2	2
166	Sensitive Gene Expression Profiling of Human T Cell Subsets Reveals Parallel Post-Thymic Differentiation for CD4+ and CD8+ Lineages. Journal of Immunology, 2007, 179, 7406-7414.	0.4	41
167	In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. Journal of Immunology, 2007, 179, 2368-2379.	0.4	26
168	IL-12 Controls Cytotoxicity of a Novel Subset of Self-Antigen-Specific Human CD28+ Cytolytic T Cells. Journal of Immunology, 2007, 178, 3566-3574.	0.4	17
169	A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide. Journal of Immunology, 2007, 179, 7635-7645.	0.4	21
170	Four Functionally Distinct Populations of Human Effector-Memory CD8+ T Lymphocytes. Journal of Immunology, 2007, 178, 4112-4119.	0.4	347
171	<i>In vivo</i> imaging of T cell delivery to tumors after adoptive transfer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12457-12461.	3.3	113
172	Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood, 2007, 110, 3564-3572.	0.6	95
173	Induction of Circulating Tumor-reactive CD8+ T Cells After Vaccination of Melanoma Patients With the gp100209-2M Peptide. Journal of Immunotherapy, 2007, 30, 533-543.	1.2	21
174	Combination of Transient Lymphodepletion With Busulfan and Fludarabine and Peptide Vaccination in a Phase I Clinical Trial for Patients With Advanced Melanoma. Journal of Immunotherapy, 2007, 30, 240-250.	1.2	27
175	Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Letters, 2007, 252, 290-298.	3.2	30
176	Toll-like Receptor 3 Expressed by Melanoma Cells as a Target for Therapy?. Clinical Cancer Research, 2007, 13, 4565-4574.	3.2	184
177	TLR3 Deficiency in Patients with Herpes Simplex Encephalitis. Science, 2007, 317, 1522-1527.	6.0	970
178	Toll-like receptors™ two-edged sword: when immunity meets apoptosis. European Journal of Immunology, 2007, 37, 3311-3318.	1.6	156
179	Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunology, Immunotherapy, 2007, 56, 839-847.	2.0	28
180	Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunology, Immunotherapy, 2007, 56, 1795-1805.	2.0	11

#	ARTICLE	IF	CITATIONS
181	Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1979-1991.	2.0	19
182	The Human T Cell Response to Melanoma Antigens. <i>Advances in Immunology</i> , 2006, 92, 187-224.	1.1	56
183	Distinct Mechanisms Control Human Naive and Antigen-Experienced CD8+ T Lymphocyte Proliferation. <i>Journal of Immunology</i> , 2006, 176, 2173-2182.	0.4	14
184	Reverse immunology approach for the identification of CD8 T cell-defined antigens: Advantages and hurdles. <i>Immunology and Cell Biology</i> , 2006, 84, 318-330.	1.0	32
185	Redirection of T Cells by Delivering a Transgenic Mouse-Derived MDM2 Tumor Antigen-Specific TCR and its Humanized Derivative Is Governed by the CD8 Coreceptor and Affects Natural Human TCR Expression. <i>Immunologic Research</i> , 2006, 34, 67-87.	1.3	43
186	Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. <i>Journal of Immunological Methods</i> , 2006, 309, 192-199.	0.6	46
187	Dextramers: New generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. <i>Journal of Immunological Methods</i> , 2006, 310, 136-148.	0.6	55
188	LiveCount Assay: Concomitant measurement of cytolytic activity and phenotypic characterisation of CD8+ T-cells by flow cytometry. <i>Journal of Immunological Methods</i> , 2006, 311, 31-46.	0.6	28
189	Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. <i>European Journal of Immunology</i> , 2006, 36, 1805-1814.	1.6	17
190	A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination. <i>Journal of Immunology</i> , 2006, 177, 1338-1348.	0.4	78
191	Ex vivo Detectable Human CD8 T-Cell Responses to Cancer-Testis Antigens. <i>Cancer Research</i> , 2006, 66, 1912-1916.	0.4	55
192	Human Effector CD8+ T Lymphocytes Express TLR3 as a Functional Coreceptor. <i>Journal of Immunology</i> , 2006, 177, 8708-8713.	0.4	112
193	Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers. <i>Journal of Immunology</i> , 2006, 177, 6769-6779.	0.4	48
194	Ex Vivo Characterization of Allo-MHC-Restricted T Cells Specific for a Single MHC-Peptide Complex. <i>Journal of Immunology</i> , 2006, 176, 2330-2336.	0.4	22
195	New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site. <i>Journal of Immunology</i> , 2006, 177, 1670-1678.	0.4	157
196	Methods for the Ex Vivo Characterization of Human CD8 <sup>+</sup> T Subsets Based on Gene Expression and Replicative History Analysis. , 2005, 109, 265-284.		15
197	Melanoma Immunotherapy: Past, Present, and Future. <i>Current Pharmaceutical Design</i> , 2005, 11, 3461-3473.	0.9	21
198	Optimum in vitro expansion of human antigen-specific CD8+ T cells for adoptive transfer therapy. <i>Clinical and Experimental Immunology</i> , 2005, 142, 292-302.	1.1	36

#	ARTICLE	IF	CITATIONS
199	High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. <i>European Journal of Immunology</i> , 2005, 35, 2876-2885.	1.6	27
200	On the significance of CD8 $\beta$ expression for T cell memory. <i>European Journal of Immunology</i> , 2005, 35, 3092-3094.	1.6	4
201	Recent advances in tumour antigen-specific therapy: In vivo veritas. <i>International Journal of Cancer</i> , 2005, 113, 173-178.	2.3	15
202	Tumor Cell Recognition Efficiency by T Cells. <i>PLoS Medicine</i> , 2005, 2, e77.	3.9	2
203	Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma. <i>Journal of Immunology</i> , 2005, 174, 1709-1716.	0.4	89
204	Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR. <i>Immunity</i> , 2005, 22, 117-129.	6.6	136
205	Tinkering with Nature: The Tale of Optimizing Peptide Based Cancer Vaccines. , 2005, 123, 267-291.		5
206	Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. <i>Journal of Clinical Investigation</i> , 2005, 115, 739-746.	3.9	569
207	Toward improved immunocompetence of adoptively transferred CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1467-1469.	3.9	28
208	Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance. <i>Cancer Research</i> , 2004, 64, 2865-2873.	0.4	351
209	Human Thymus Exports Naive CD8 T Cells That Can Home to Nonlymphoid Tissues. <i>Journal of Immunology</i> , 2004, 172, 2773-2777.	0.4	19
210	Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma. <i>Cancer Research</i> , 2004, 64, 2192-2198.	0.4	94
211	Final Antigenic Melan-A Peptides Produced Directly by the Proteasomes Are Preferentially Selected for Presentation by HLA-A*0201 in Melanoma Cells. <i>Journal of Immunology</i> , 2004, 173, 6033-6040.	0.4	21
212	High Frequency of Functionally Active Melan-A-Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma. <i>Cancer Research</i> , 2004, 64, 6319-6326.	0.4	60
213	gp100 $\alpha$ 2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells. <i>Clinical Cancer Research</i> , 2004, 10, 668-680.	3.2	74
214	Reduced L-selectin (CD62L) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. <i>Cellular Immunology</i> , 2004, 227, 93-102.	1.4	11
215	Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 249-255.	2.0	70
216	Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon- $\gamma$ ELISPOT Assays for Patient Immune Monitoring. <i>Journal of Immunotherapy</i> , 2004, 27, 298-308.	1.2	40

#	ARTICLE	IF	CITATIONS
217	Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. <i>Cancer Immunity</i> , 2004, 4, 4.	3.2	36
218	Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. <i>Seminars in Cancer Biology</i> , 2003, 13, 461-472.	4.3	50
219	Adjuvant Immunization of HLA-A2 <sup>+</sup> Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8 <sup>+</sup> T-Cell Responses. <i>Journal of Clinical Oncology</i> , 2003, 21, 1562-1573.	0.8	107
220	Î±3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells. <i>Journal of Immunology</i> , 2003, 171, 1844-1849.	0.4	65
221	Prevalent Role of TCR Î±-Chain in the Selection of the Preimmune Repertoire Specific for a Human Tumor-Associated Self-Antigen. <i>Journal of Immunology</i> , 2003, 170, 5103-5109.	0.4	76
222	Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells. <i>Blood</i> , 2003, 102, 1241-1248.	0.6	21
223	Ex vivo characterization of human CD8 <sup>+</sup> T subsets with distinct replicative history and partial effector functions. <i>Blood</i> , 2003, 102, 1779-1787.	0.6	167
224	Activation of human melanoma reactive CD8 <sup>+</sup> T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. <i>Clinical Cancer Research</i> , 2003, 9, 669-77.	3.2	37
225	Disease-driven T cell activation predicts immune responses to vaccination against melanoma. <i>Cancer Immunity</i> , 2003, 3, 12.	3.2	8
226	Tumor-reactive, SSX-2-specific CD8 <sup>+</sup> T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. <i>Cancer Research</i> , 2003, 63, 5601-6.	0.4	40
227	Simultaneous CD8 <sup>+</sup> T cell responses to multiple tumor antigen epitopes in a multi-peptide melanoma vaccine. <i>Cancer Immunity</i> , 2003, 3, 15.	3.2	29
228	Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma. <i>Journal of Immunology</i> , 2002, 168, 1717-1722.	0.4	106
229	CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide. <i>Journal of Immunology</i> , 2002, 168, 1212-1218.	0.4	135
230	Positional Scanning-Synthetic Peptide Library-Based Analysis of Self- and Pathogen-Derived Peptide Cross-Reactivity with Tumor-Reactive Melan-A-Specific CTL. <i>Journal of Immunology</i> , 2002, 169, 5696-5707.	0.4	57
231	Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR. <i>Journal of Immunology</i> , 2002, 168, 1167-1171.	0.4	67
232	Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans. <i>Journal of Experimental Medicine</i> , 2002, 195, 485-494.	4.2	136
233	Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity. <i>Journal of Immunology</i> , 2002, 168, 4231-4240.	0.4	113
234	Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer <sup>+</sup> CD8 <sup>+</sup> T Cells in Humans. <i>Journal of Experimental Medicine</i> , 2002, 196, 207-216.	4.2	90



#	ARTICLE	IF	CITATIONS
235	Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. <i>Trends in Immunology</i> , 2002, 23, 325-328.	2.9	53
236	Degeneracy instead of specificity: is this a solution to cancer immunotherapy?. <i>Trends in Immunology</i> , 2002, 23, 344.	2.9	2
237	Therapeutic cancer vaccines based on molecularly defined human tumor antigens. <i>Vaccine</i> , 2002, 20, A2-A7.	1.7	9
238	In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. <i>European Journal of Immunology</i> , 2002, 32, 731.	1.6	96
239	Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity. <i>European Journal of Immunology</i> , 2002, 32, 2292.	1.6	37
240	Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. <i>European Journal of Immunology</i> , 2002, 32, 3285-3293.	1.6	22
241	Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. <i>International Journal of Cancer</i> , 2002, 99, 201-206.	2.3	4
242	Loss of single HLA Class I allospecificities in melanoma cells due to selective genomic abbreviations. <i>International Journal of Cancer</i> , 2002, 99, 82-87.	2.3	18
243	Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: Advantages and limitations. <i>Cytometry</i> , 2002, 48, 97-105.	1.8	51
244	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. <i>Immunological Reviews</i> , 2002, 188, 81-96.	2.8	146
245	Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. <i>Oncogene</i> , 2002, 21, 5213-5223.	2.6	194
246	Modulation of proteasomal activity in vitro induces the generation of an HLA-A*0201 specific CTL-defined epitope derived from the melanoma-associated antigen MAGE-3. , 2002, , 693-694.		0
247	Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. <i>Cancer Research</i> , 2002, 62, 1743-50.	0.4	70
248	Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8+ Tumor-reactive T-Cell Ligands: a comparative analysis of PS-SCL recognition by a single tumor-reactive CD8+ cytolytic T-lymphocyte clone. <i>Cancer Research</i> , 2002, 62, 2058-63.	0.4	19
249	Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?. <i>Cancer Immunity</i> , 2002, 2, 14.	3.2	10
250	Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. <i>International Immunopharmacology</i> , 2001, 1, 1235-1247.	1.7	42
251	Expression of melan-a/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. <i>International Journal of Cancer</i> , 2001, 95, 73-77.	2.3	38
252	Human CD8+ T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. <i>European Journal of Immunology</i> , 2001, 31, 459-466.	1.6	48

#	ARTICLE	IF	CITATIONS
253	Lack of tumor recognition by hTERT peptide 540-548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. <i>European Journal of Immunology</i> , 2001, 31, 2642-2651.	1.6	76
254	Ex Vivo IFN- $\beta$ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases. <i>Journal of Immunology</i> , 2001, 166, 7634-7640.	0.4	135
255	Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes. <i>Journal of Immunology</i> , 2001, 167, 3276-3284.	0.4	75
256	The Activatory Receptor 2B4 Is Expressed In Vivo by Human CD8+ Effector $\gamma\delta$ T Cells. <i>Journal of Immunology</i> , 2001, 167, 6165-6170.	0.4	82
257	Cancer Vaccine Design: A Novel Bacterial Adjuvant for Peptide-Specific CTL Induction. <i>Journal of Immunology</i> , 2001, 166, 4612-4619.	0.4	47
258	A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy. <i>Journal of Immunology</i> , 2001, 167, 5852-5861.	0.4	44
259	Subcellular Localization of the Melanoma-associated Protein Melan-AMART-1 Influences the Processing of Its HLA-A2-restricted Epitope. <i>Journal of Biological Chemistry</i> , 2001, 276, 43189-43196.	1.6	26
260	Lack of tumor recognition by hTERT peptide 540-548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. , 2001, 31, 2642.		1
261	Generation and characterization of malaria-specific human CD8+ lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentation by liver cells. <i>European Journal of Immunology</i> , 2000, 30, 3079-3088.	1.6	38
262	Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. <i>European Journal of Immunology</i> , 2000, 30, 3165-3170.	1.6	26
263	HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new <i>Plasmodium falciparum</i> epitopes by IFN-gamma ELISPOT. <i>Parasite Immunology</i> , 2000, 22, 501-514.	0.7	39
264	OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. <i>Nature Immunology</i> , 2000, 1, 502-509.	7.0	198
265	Quantitation of antigen-reactive T cells in peripheral blood by IFN- $\gamma$ -ELISPOT assay and chromium-release assay: a four-centre comparative trial. <i>Journal of Immunological Methods</i> , 2000, 244, 81-89.	0.6	131
266	Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. <i>Journal of Immunological Methods</i> , 2000, 237, 159-173.	0.6	48
267	Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface Expression. <i>Journal of Immunology</i> , 2000, 164, 1148-1152.	0.4	232
268	Tetramer-Guided Analysis of TCR $\beta$ -Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients. <i>Journal of Immunology</i> , 2000, 165, 533-538.	0.4	84
269	Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma. <i>Journal of Immunology</i> , 2000, 165, 7253-7261.	0.4	77
270	Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue. <i>Journal of Immunology</i> , 2000, 164, 1125-1131.	0.4	75



#	ARTICLE	IF	CITATIONS
271	Amino Acid Identity and/or Position Determines the Proteasomal Cleavage of the HLA-A*0201-restricted Peptide Tumor Antigen MAGE-3271â€“279. <i>Journal of Biological Chemistry</i> , 2000, 275, 26892-26897.	1.6	13
272	In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanomaâ€“Specific Cytolytic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1999, 190, 775-782.	4.2	179
273	Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. <i>International Immunology</i> , 1999, 11, 1971-1980.	1.8	49
274	High Frequencies of Naive Melan-a/Mart-1â€“Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals. <i>Journal of Experimental Medicine</i> , 1999, 190, 705-716.	4.2	447
275	Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyteâ€“defined Peptide Derived from the Tumor Antigen MAGE-3. <i>Journal of Experimental Medicine</i> , 1999, 189, 895-906.	4.2	116
276	BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth. <i>Journal of Experimental Medicine</i> , 1999, 189, 1747-1756.	4.2	1,213
277	Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. <i>Tissue Antigens</i> , 1999, 53, 519-526.	1.0	5
278	Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 735-741.	0.4	26
279	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. <i>European Journal of Immunology</i> , 1999, 29, 1990-1999.	1.6	111
280	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. , 1999, 29, 1990.		1
281	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. , 1999, 29, 1990.		7
282	Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. <i>Trends in Molecular Medicine</i> , 1998, 4, 305-312.	2.6	78
283	Circulating MELAN-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. <i>International Journal of Cancer</i> , 1998, 78, 699-706.	2.3	66
284	Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1998, 188, 1641-1650.	4.2	475
285	High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo. <i>Journal of Experimental Medicine</i> , 1998, 188, 1203-1208.	4.2	408
286	Circulating MELANâ€“A/MARTâ€“1 specific cytolytic T lymphocyte precursors in HLAâ€“A2 melanoma patients have a memory phenotype. <i>International Journal of Cancer</i> , 1998, 78, 699-706.	2.3	1
287	Differential Roles of T Cell Receptor Î± and Î² Chains in Ligand Binding Among H-2Kd-restricted Cytolytic T Lymphocyte Clones Specific for a Photoreactive Plasmodium berghei Circumsporozoite Peptide Derivative. <i>Journal of Biological Chemistry</i> , 1997, 272, 8505-8514.	1.6	19
288	Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen. <i>International Journal of Cancer</i> , 1997, 72, 1045-1055.	2.3	9

#	ARTICLE	IF	CITATIONS
289	N-acetyl-L-cysteine Exhibits Antitumoral Activity by Increasing Tumor Necrosis Factor $\hat{\pm}$ -Dependent T-Cell Cytotoxicity. <i>Blood</i> , 1997, 90, 1124-1132.	0.6	7
290	Recognition of tumor-associated antigens by T-lymphocytes: Perspectives for peptide-based vaccines. <i>Annals of Oncology</i> , 1996, 7, 339-342.	0.6	2
291	A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. <i>Immunogenetics</i> , 1996, 43, 377-383.	1.2	98
292	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides <i>in vivo</i> : Implications for tumor vaccines with melanoma-associated antigens. , 1996, 66, 162-169.		200
293	Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. <i>Seminars in Immunopathology</i> , 1996, 18, 185-198.	4.0	12
294	The Majority of Autologous Cytolytic T-Lymphocyte Clones Derived from Peripheral Blood Lymphocytes of a Melanoma Patient Recognize an Antigenic Peptide Derived from Gene Pmel17/gp100. <i>Journal of Investigative Dermatology</i> , 1996, 107, 63-67.	0.3	54
295	CD8 $\hat{\pm}$ Increases CD8 Coreceptor Function and Participation in TCR $\hat{\pm}$ Ligand Binding. <i>Journal of Experimental Medicine</i> , 1996, 184, 2439-2444.	4.2	79
296	HLA Photoaffinity Labeling Reveals Overlapping Binding of Homologous Melanoma-associated Gene Peptides by HLA-A1, HLA-A29, and HLA-B44. <i>Journal of Biological Chemistry</i> , 1996, 271, 12463-12471.	1.6	22
297	CD8 modulation of T-cell antigen receptor $\hat{\pm}$ ligand interactions on living cytotoxic T lymphocytes. <i>Nature</i> , 1995, 373, 353-356.	13.7	231
298	CD8+ T-cell protective immunity induced by immunization with <i>Plasmodium berghei</i> CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. <i>Immunology Letters</i> , 1995, 46, 199-205.	1.1	31
299	Structural analysis of TCR-ligand interactions studied on H-2Kd-restricted cloned CTL specific for a photoreactive peptide derivative. <i>Immunity</i> , 1995, 3, 51-63.	6.6	50
300	Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): Further enhancement by pre-injection of IFA alone. <i>European Journal of Immunology</i> , 1994, 24, 1458-1462.	1.6	42
301	Leishmania major infection in mice primes for specific major histocompatibility complex class I-restricted CD8+ cytotoxic T cell responses. <i>European Journal of Immunology</i> , 1994, 24, 2813-2817.	1.6	58
302	Efficient <i>in vivo</i> induction of CTL by cell-associated covalent H-2Kd-peptide complexes. <i>Journal of Immunological Methods</i> , 1994, 171, 73-84.	0.6	11
303	Letter to the editor. <i>International Journal of Cancer</i> , 1993, 54, 527-528.	2.3	84
304	MHC class I H-2Kd-restricted antigenic peptides: additional constraints for the binding motif. <i>International Immunology</i> , 1993, 5, 1489-1492.	1.8	21
305	Differential T cell receptor photoaffinity labeling among H-2Kd restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. Labeling of the alpha-chain correlates with J alpha segment usage.. <i>Journal of Experimental Medicine</i> , 1993, 177, 1247-1256.	4.2	24
306	T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. <i>Journal of Immunological Methods</i> , 1992, 155, 95-99.	0.6	91

#	ARTICLE	IF	CITATIONS
307	Specific binding of antigenic peptides to cell-associated MHC class I molecules. <i>Nature</i> , 1991, 351, 72-74.	13.7	49
308	CD8+ cytolytic T cell clones derived against the <i>Plasmodium yoelii</i> circumsporozoite protein protect against malaria. <i>International Immunology</i> , 1991, 3, 579-585.	1.8	216
309	The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. <i>International Immunology</i> , 1991, 3, 1035-1042.	1.8	38
310	Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. <i>Immunology Letters</i> , 1990, 25, 27-31.	1.1	36
311	Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. <i>Nature</i> , 1989, 341, 323-326.	13.7	501
312	A synthetic vaccine protects humans against challenge with asexual blood stages of <i>Plasmodium falciparum</i> malaria. <i>Nature</i> , 1988, 332, 158-161.	13.7	415
313	Induction of protective immunity against experimental infection with malaria using synthetic peptides. <i>Nature</i> , 1987, 328, 629-632.	13.7	296